The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.
<h4>Objectives</h4>To compare clinical outcomes of concurrent chemoradiotherapy (CCRT) with those of radiotherapy alone for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy (IMRT) era.<h4>Materials and methods</h4>We comprehensively searched PubMed, E...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0194733 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839655795779698688 |
|---|---|
| author | Fang Liu Tao Jin Lei Liu Zhongzheng Xiang Ruonan Yan Hui Yang |
| author_facet | Fang Liu Tao Jin Lei Liu Zhongzheng Xiang Ruonan Yan Hui Yang |
| author_sort | Fang Liu |
| collection | DOAJ |
| description | <h4>Objectives</h4>To compare clinical outcomes of concurrent chemoradiotherapy (CCRT) with those of radiotherapy alone for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy (IMRT) era.<h4>Materials and methods</h4>We comprehensively searched PubMed, Embase, and the Cochrane Library to identify eligible studies. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) with hazard ratios (HRs), and toxicities with odd ratios (ORs) were analyzed.<h4>Results</h4>A total of seven studies met the criteria, with 1302 patients who were treated with IMRT alone or IMRT plus concurrent chemotherapy. No significant survival benefit was shown by CCRT regardless of OS (HR = 1.17, 95% CI 0.73-1.89, P = 0.508), PFS (HR = 0.76, 95% CI 0.38-1.50, P = 0.430), DMFS (HR = 0.89, 95% CI 0.33-2.41, P = 0.816), or LRRFS (HR = 1.03, 95% CI 0.95-1.12, P = 0.498). Additionally, CCRT notably increased the risk of acute grade 3-4 leukopenia (OR = 4.432, 95% CI 2.195-8.952, P < 0.001), compared to IMRT alone.<h4>Conclusion</h4>Adding concurrent chemotherapy to IMRT led to no survival benefit and increased acute toxicity reactions for stage II nasopharyngeal carcinoma. |
| format | Article |
| id | doaj-art-94b6ec35ba804977a7d726491f78fce6 |
| institution | Matheson Library |
| issn | 1932-6203 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-94b6ec35ba804977a7d726491f78fce62025-06-25T05:31:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01133e019473310.1371/journal.pone.0194733The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.Fang LiuTao JinLei LiuZhongzheng XiangRuonan YanHui Yang<h4>Objectives</h4>To compare clinical outcomes of concurrent chemoradiotherapy (CCRT) with those of radiotherapy alone for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy (IMRT) era.<h4>Materials and methods</h4>We comprehensively searched PubMed, Embase, and the Cochrane Library to identify eligible studies. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) with hazard ratios (HRs), and toxicities with odd ratios (ORs) were analyzed.<h4>Results</h4>A total of seven studies met the criteria, with 1302 patients who were treated with IMRT alone or IMRT plus concurrent chemotherapy. No significant survival benefit was shown by CCRT regardless of OS (HR = 1.17, 95% CI 0.73-1.89, P = 0.508), PFS (HR = 0.76, 95% CI 0.38-1.50, P = 0.430), DMFS (HR = 0.89, 95% CI 0.33-2.41, P = 0.816), or LRRFS (HR = 1.03, 95% CI 0.95-1.12, P = 0.498). Additionally, CCRT notably increased the risk of acute grade 3-4 leukopenia (OR = 4.432, 95% CI 2.195-8.952, P < 0.001), compared to IMRT alone.<h4>Conclusion</h4>Adding concurrent chemotherapy to IMRT led to no survival benefit and increased acute toxicity reactions for stage II nasopharyngeal carcinoma.https://doi.org/10.1371/journal.pone.0194733 |
| spellingShingle | Fang Liu Tao Jin Lei Liu Zhongzheng Xiang Ruonan Yan Hui Yang The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. PLoS ONE |
| title | The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. |
| title_full | The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. |
| title_fullStr | The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. |
| title_full_unstemmed | The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. |
| title_short | The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis. |
| title_sort | role of concurrent chemotherapy for stage ii nasopharyngeal carcinoma in the intensity modulated radiotherapy era a systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0194733 |
| work_keys_str_mv | AT fangliu theroleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT taojin theroleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT leiliu theroleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT zhongzhengxiang theroleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT ruonanyan theroleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT huiyang theroleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT fangliu roleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT taojin roleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT leiliu roleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT zhongzhengxiang roleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT ruonanyan roleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis AT huiyang roleofconcurrentchemotherapyforstageiinasopharyngealcarcinomaintheintensitymodulatedradiotherapyeraasystematicreviewandmetaanalysis |